Matches in Wikidata for { <http://www.wikidata.org/entity/Q56977321> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q56977321 description "article scientifique publié en 2013" @default.
- Q56977321 description "article" @default.
- Q56977321 description "im Oktober 2013 veröffentlichter wissenschaftlicher Artikel" @default.
- Q56977321 description "wetenschappelijk artikel" @default.
- Q56977321 description "наукова стаття, опублікована в жовтні 2013" @default.
- Q56977321 name "Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?" @default.
- Q56977321 name "Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?" @default.
- Q56977321 type Item @default.
- Q56977321 label "Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?" @default.
- Q56977321 label "Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?" @default.
- Q56977321 prefLabel "Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?" @default.
- Q56977321 prefLabel "Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?" @default.
- Q56977321 P1433 Q56977321-87660F16-3DA0-42E1-AF31-3519FFBD1E3F @default.
- Q56977321 P1476 Q56977321-8B8C6B7F-C1B1-421F-8D43-95C88F4BB6AA @default.
- Q56977321 P2093 Q56977321-5BF05889-BFD6-48C3-A656-45CF8EBEC191 @default.
- Q56977321 P2093 Q56977321-90EC7F2F-03CB-4806-A675-17B33E6C7C6A @default.
- Q56977321 P2093 Q56977321-9E365678-668B-4412-9AB7-5A4078BA844E @default.
- Q56977321 P2093 Q56977321-C509B11B-6359-46C9-AA36-655D6D221E34 @default.
- Q56977321 P304 Q56977321-721AACD2-18EB-42D5-B3D1-DD02552CF015 @default.
- Q56977321 P31 Q56977321-FD4AB954-26EB-4936-92A8-38F458DCE60A @default.
- Q56977321 P356 Q56977321-2520DBBC-60D6-4B98-BF4C-436BAB50EDB6 @default.
- Q56977321 P407 Q56977321-CE4540A5-7394-4063-BE72-8F2A4C77920A @default.
- Q56977321 P433 Q56977321-A6B4026D-B6C7-49AA-8A87-B5E2F0A74114 @default.
- Q56977321 P478 Q56977321-AC8BB3D1-58DF-4060-9A03-56BA71E72FBF @default.
- Q56977321 P577 Q56977321-52C15C2A-2287-46B5-BB59-735CF7306670 @default.
- Q56977321 P698 Q56977321-F3F6FE5C-3A36-4878-A538-C11543AF7FDC @default.
- Q56977321 P921 Q56977321-351F98BF-BCB0-41DB-98EF-F65A2C200DFE @default.
- Q56977321 P356 MCG.0B013E3182951B6C @default.
- Q56977321 P698 23751850 @default.
- Q56977321 P1433 Q15710046 @default.
- Q56977321 P1476 "Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?" @default.
- Q56977321 P2093 "Cecilia Renzulli" @default.
- Q56977321 P2093 "Fiorella Calanni" @default.
- Q56977321 P2093 "Maria V Fogli" @default.
- Q56977321 P2093 "Miriam Barbanti" @default.
- Q56977321 P304 "814" @default.
- Q56977321 P31 Q13442814 @default.
- Q56977321 P356 "10.1097/MCG.0B013E3182951B6C" @default.
- Q56977321 P407 Q1860 @default.
- Q56977321 P433 "9" @default.
- Q56977321 P478 "47" @default.
- Q56977321 P577 "2013-10-01T00:00:00Z" @default.
- Q56977321 P698 "23751850" @default.
- Q56977321 P921 Q63391344 @default.